The Current Ratio as of November 2024 (TTM) for Dyne Therapeutics, Inc. (DYN) is 26.63

According to Dyne Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 26.63. This represents a change of 89.18% compared to the average of 14.08 of the last 4 quarters.

Dyne Therapeutics, Inc. (DYN) Historical Current Ratio (quarterly & annually)

How has DYN Current Ratio performed in the past?

The mean historical Current Ratio of Dyne Therapeutics, Inc. over the last ten years is 8.52. The current 26.63 Current Ratio has changed 31.15% with respect to the historical average. Over the past ten years (40 quarters), DYN's Current Ratio was at its highest in in the September 2020 quarter at 81.20. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Dyne Therapeutics, Inc. (DYN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Dyne Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dyne Therapeutics, Inc. (DYN) Average Current Ratio

How has DYN Current Ratio performed in the past?

The current Current Ratio of Dyne Therapeutics, Inc. (DYN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Dyne Therapeutics, Inc. (DYN) Current Ratio vs. Peers

How is DYN’s Current Ratio compared to its peers?

Dyne Therapeutics, Inc.’s Current Ratio is greater than Stoke Therapeutics, Inc. (6.67), greater than Pliant Therapeutics, Inc. (14.47), greater than Cytokinetics, Incorporated (10.39), greater than Revolution Medicines, Inc. (15.42), less than Edgewise Therapeutics, Inc. (30.24), less than Cullinan Oncology, Inc. (28.87), greater than Mineralys Therapeutics, Inc. (11.20), greater than DICE Therapeutics, Inc. (25.88), greater than Karuna Therapeutics, Inc. (19.31), greater than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), greater than Erasca, Inc. (16.79),

Build a custom stock screener for Dyne Therapeutics, Inc. (DYN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dyne Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dyne Therapeutics, Inc. (DYN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dyne Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.